ClinicalTrials.gg
RecruitingNCT06995378Updated Jul 9, 2026

Study EHR Risk Stratification Tools

An interventional study of Hemoglobin A1c Lab Result Communication Tool in Prediabetes, Health Communication and Patient Comprehension, sponsored by University of California, Los Angeles. Recruiting at 1 site in United States. Open to participants aged 65 Years and older. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by University of California, Los Angeles · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Randomized
Ages
65 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.

Planned enrollment
12th of 362
1,200 · median 54
Started
2026
with 38 others
No phase
288 of 390
58 open now
Primary completion
2026-11
later than 22 of 106 live
Registered
345th of 390
by date
Lead sponsor
8 of 390
University of California, Los Angeles

Among the 390 studies in Prediabetic State with a site in United States, this one is the 12th largest by planned enrollment of the 362 interventional ones that give a count, is one of 39 that started in 2026, is one of 288 with no phase, reaches primary completion later than 22 of the 106 other live ones, and was the 345th registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 65 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Prediabetic State with a site in United States, or all of them as a file.
02

Study summary

This study evaluates whether adding machine learning-based risk information to electronic health record (EHR) lab result messages helps older adults better understand their risk of developing diabetes and influences their emotional responses, quality of life, and healthcare use.

Eligible participants are adults aged 65 years and older with a UCLA primary care provider and a hemoglobin A1c level in the range (5.7-6.0%). Participants are identified automatically at the time their lab results are processed and are randomly assigned to receive either standard lab result messages or modified messages that include a "very low risk" label generated by a machine learning model.

All participants who are randomized are invited to complete two surveys: one shortly after their lab result is posted in MyChart and a follow-up survey approximately 30 days later. The study also uses de-identified EHR data to examine patterns of healthcare utilization and progression to diabetes. Provider comments related to lab result messaging will be analyzed to explore differences in response patterns between the two groups.

Read the detailed description

Prediabetes thresholds based on hemoglobin A1c were originally developed using younger, healthier populations and may not reflect the slower and more variable glycemic changes observed in older adults. Evidence from large community-based cohorts suggests that adults aged 65 years and older with A1c values in the prediabetes range are often more likely to return to normal glycemia than to progress to diabetes, creating uncertainty for patients and providers when interpreting lab results.

Machine learning models developed using de-identified UCLA Health EHR data from multiple annual cohorts between 2020 and 2024 demonstrated strong performance in predicting progression to diabetes. The final model uses a CatBoost architecture and incorporates approximately 94 routinely collected clinical variables to generate patient-specific risk scores. Model performance was evaluated across yearly cohorts, and the selected model is locked for the duration of the study without updating or adapting to new data.

The study follows a real-world, randomized deployment design in which eligible individuals in the lowest 15% of model-predicted risk within the eligible study population are identified automatically at the time lab results are processed and assigned to either modified or standard lab result messaging. De-identified EHR data and free-text provider comments are used to examine healthcare utilization, disease progression, and provider response patterns over time.

All participants who are randomized are invited to complete two surveys. The first survey is administered shortly after receipt of the laboratory result and is designed to assess immediate patient understanding of the result and emotional responses such as anxiety or reassurance. A second survey is administered approximately one month later and uses validated instruments to measure health-related quality of life, food-related quality of life and eating behavior, and perceived burden of healthcare. Both study arms receive the same surveys, allowing comparison of patient-reported outcomes between standard and modified laboratory result messaging. Surveys are distributed only to participants who have been randomized to either modified or standard laboratory result messaging. Therefore, no additional eligibility criteria apply for survey participation beyond randomization.

By embedding model-generated risk information directly into routine EHR workflows, this study aims to generate evidence on whether precision-based communication can support more individualized, patient-centered care and inform future implementation across broader patient populations and clinical use cases.

03

Conditions studied

  • Prediabetes
  • Health Communication
  • Patient Comprehension

Browse trials for

Keywords

  • Prediabetes
  • Machine Learning
  • Risk Stratification
  • Electronic Health Record
  • Lab Result Communication
  • Predictive Modeling
  • Patient Comprehension
04

Who can participate

Ages eligible
65 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 65 years or older
  • in the prediabetes range (5.7- but not including 6.0%)

Exclusion criteria

Exclusion Criteria:

  • Have lab results outside the defined inclusion range
  • No UCLA primary care provider
  • Age \<65 years
  • Eligibility for Surveys:

All randomized participants are eligible to receive study surveys. No additional eligibility criteria apply for survey participation.

HgbA1c of 6.0 or above is not eligible.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • Experimental
    Personalized Lab Result Messaging

    Participants receive modified electronic health record (EHR) lab result communications in the patient portal (MyChart) and provider-facing EHR interface that include a qualitative "very low risk" label generated by a machine learning-based tool, along with brief explanatory text providing context about their current results and indicating a low level of concern at this time.

    Device: Hemoglobin A1c Lab Result Communication Tool

  • No intervention
    Standard Lab Result Messaging

    Participants receive standard electronic health record (EHR) lab result communications without any machine learning-generated risk labeling or explanatory text providing additional context about level of concern.

Interventions

  • DeviceHemoglobin A1c Lab Result Communication Tool

    A behavioral intervention delivered through a personalized Electronic Health Record (EHR)-integrated lab result communication tool designed to improve emotional and cognitive responses to lab results among adults aged 65+. The tool applies behavioral science principles such as risk personalization, simplified messaging, and visual framing to reduce patient anxiety, enhance understanding, and support informed decision-making.

06

What researchers measure

Primary outcomes

  1. Prediabetes- Related Healthcare Utilization

    Total count of prediabetes-related healthcare utilization defined as the sum of outpatient visits to endocrinology, repeat hemoglobin A1c tests, and new prescriptions for diabetes-related medications following the index A1c result.

    Time frame: 365 days after result

Secondary outcomes

  1. Number of Repeat Hemoglobin A1c Tests

    Total number of repeat hemoglobin A1c laboratory tests performed after the index test. This measure reflects follow-up glycemic testing and serves as an indicator of diabetes-related monitoring and healthcare utilization.

    Time frame: 365 days after result

  2. Number of Prescriptions for Diabetes-Related Medications

    Total number of prescriptions issued for medications commonly used for glycemic management (e.g., metformin) following the index hemoglobin A1c result. This outcome captures initiation of pharmacologic treatment related to diabetes risk.

    Time frame: 180 days after result

  3. Total Number of Outpatient Healthcare

    Total count of outpatient visits across all specialties following the index A1c result

    Time frame: 180 days after result

  4. Numbers of Referrals to Endocrinology

    Total number of outpatient referrals to an endocrinologist occurring after the index hemoglobin A1c laboratory result. This measure is used to quantify diabetes-related specialty care utilization potentially associated with interpretation of the laboratory result communication.

    Time frame: 14 days after initial result

  5. Number of Referrals to Nutrition Services

    Number of participants with an electronic referral order placed to clinical nutrition services documented in the electronic health record after release of the hemoglobin A1c result.

    Time frame: 14 days after initial result

  6. Number of Referrals to Diabetes Education

    Number of participants with an electronic referral order placed to diabetes education services documented in the electronic health record after release of the hemoglobin A1c result.

    Time frame: 14 days after initial result

  7. Number of Completed Endocrinology Visit

    Number of participants who complete an outpatient endocrinology encounter documented in the electronic health record after laboratory result notification. Visit completion will be identified using encounter records associated with endocrinology clinic services.

    Time frame: 180 days after result

  8. Completed Nutrition Services Visit

    Number of participants who complete an outpatient visit with clinical nutrition services documented in the electronic health record following laboratory result notification. Completion will be determined using encounter data associated with nutrition services.

    Time frame: 180 days after result

  9. Completed Appointments to Diabetes Education

    Number of participants who complete an outpatient visit with diabetes education services documented in the electronic health record following laboratory result notification. Completion will be determined using encounter data associated with diabetes education.

    Time frame: 180 days after result

  10. Number of Patient MyChart Messages

    Count of MyChart Test Result Messages

    Time frame: 7 days after viewing lab result

  11. Numbers of Phone Calls Received after A1c Results

    Count of telephone encounters to ordering provider

    Time frame: 7 days after viewing lab result

Other outcomes

  1. Self-Reported Quality of Life

    Patient-reported quality of life assessed using survey responses evaluating overall physical, mental, and health-related well-being following receipt of lab result communication.

    Time frame: 30 days after initial survey invitation

  2. Self-Reported Physical Function Following Lab Result

    Self-reported physical function asking about ability to perform activities such as household chores, stair climbing, walking, and running errands following receipt of lab result communication. This measure uses structured survey items to evaluate whether receipt of A1c lab result communication is associated with changes in exercise.

    Time frame: 30 days after initial survey invitation

  3. Self-Reported Dietary Behaviors Following Lab Result

    Patient-reported dietary behaviors following receipt of lab result, including eating patterns, appetite, satiety, and food-related changes or restrictions due to concerns about lab results. These behaviors are assessed to understand potential impacts on health and weight-related decision-making. This measure uses structured survey items to evaluates whether receipt of A1c lab result communication is associated with changes dietary behaviors.

    Time frame: 30 days after initial survey invitation

  4. Patient Understanding and Anxiety Related to Lab Result Communication

    Patient-reported understanding of lab report and emotional response to result communication, including perceived clarity, reassurance, and level of concern, assessed using structured survey items designed to measure comprehension and anxiety following receipt of laboratory result messaging.

    Time frame: 7 days after results

  5. Number of Incidence of Diabetes

    Proportion of participants who progress from prediabetes to diabetes based on electronic health record data, defined by meeting diagnostic criteria for diabetes during follow-up. This outcome is included to monitor long-term clinical safety and progression.

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Nov 2026, 6 months after the start.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's planned 6 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2025
First posted
May 29, 2025
StartActual
May 27, 2026
Primary completionEst.
Nov 2026
CompletionEst.
Sep 2029
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06995378
Responsible party
Catherine A. Sarkisian (Professor of Medicine, University of California, Los Angeles) — Principal investigator
First posted
May 29, 2025
Start date
May 27, 2026
Primary completion
Nov 2026 (estimated)
Completion
Sep 2029 (estimated)
Last update
Jul 9, 2026

Study contacts

Katelyn Nguyen Assistant Clinical Research Coordinator
Contact
katenguyen@mednet.ucla.edu
310-267-5250

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion